A brief history of levodopa

Journal of Neurology

Volumn 257, Issue SUPPL. 2, 2010, Pages

  Hornykiewicz, Oleh ^a  

^a Medical University of Vienna   (Austria)

Author keywords

History of parkinson's disease; Levodopa therapy; Striatal and nigral dopamine deficit

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; LEVODOPA; ANTIPARKINSON AGENT;

BASAL GANGLION; CONFERENCE PAPER; CORPUS STRIATUM; HISTORY OF MEDICINE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; BRAIN LEVEL; DRUG EFFECT; HISTORY; PHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN CHEMISTRY; DOPAMINE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEVODOPA; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 79960696174     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5741-y     Document Type: Conference Paper

References (37)

1. Torquati T (1913) Sulla presenza di una sostanza azotata nei germogli del semi di "vicia faba". Arch Farmacol sper 15:213-223
2. GuggenheirnM(1913) Dioxyphenylalanin, eine neue Aminosäure ausVicia faba. Hoppe-Seyler's Z Physiol Chem 88:276-284
3. Holtz P (1939) Dopadecarboxylase. Naturwissenschaften 27:724-725
4. Blaschko H (1939) The specific action of L-dopa decarboxylase. J Physiol 96:50P-51P
5. Holtz P, Heise R, Lüdke K (1938) Fermentativer Abbau von l-Dioxyphenylalanin durch die Niere. Arch Exp Path Pharmak 191:87-118
6. Hornykiewicz O (2002) L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23:65-70
7. Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180:244-245
8. Weil-Malherbe H, Bone AD (1957) Intracellular distribution of catecholamines in the brain. Nature 180:1050-1051
9. Holtz P, Balzer H, Westermann E, Wezler E (1957) Beeinflussung der Evipannarkose durch Reserpin, Iproniazid und biogene Amine. Arch Exp Path Pharmak 131:333-348
10. Carlsson A, Lindqvist M, Magnusson T (1957) 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptamine as reserpine antagonists. Nature 127:471
11. Pletscher A (1957) Wirckung von Isopropyl-Isonikotinsäurehydrazid auf den Stoffwechsel von Catecholaminen und 5-Hydroxytryptamin im Gehirn. Schweiz Med Wochenschr 87:1532-1534
12. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127:471
13. Weil-Malherbe H, Bone AD (1958) Effect of reserpine on the intracellular distribution of catecholamines in the brain. Nature 181:1474-1475
14. Bertler Å, Rosengren E (1959) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15:10-11
15. Sano L, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in the human brain. Biochim Biophys Acta 32:586-587
16. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wschr 38:1236-1239
17. Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanin (DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wschr 73:787-788
18. Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenylalanin-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiat Nervenkr 203:560-574
19. Cotzias CC, Van Woert MH, Schiffer IM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374-379
20. Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin and Dopamin in der Substantia nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 75:309-312
21. Dahlström A, Fuxe K (1964) Evidence far the existence of monoamine-containing neurons in the central nervous system. 1. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 62(Suppl 232):1-55
22. Poirier LJ, Sourkes TL (1964) Influance de locus niger sur la concentration des catecholamines du striatum. J Physiol (Paris) 56:426-427
23. Sourkes TL, Poirier LJ (1965) Influence of the substantia nigra on the concentration of 5-hydroxytryptarnine and dopamine of the striatum. Nature 207:202-203
24. Denny-Brown D (1962) The basal ganglia and their relation to disorders of movement. Oxford University Press, Oxford
25. Mettler FA (1964) Substantia nigra and parkinsonism. Arch Neurol 11:529-542
26. Carpenter M (1966) Discussion in: Costa E, Cote LJ, Yahr MD (eds) Biochemistry and Pharmacology of the Basal Ganglia. Hewlett, Raven Press, p. 191
27. Hassler R (1967) Private communication to O. Hornykiewicz. Letter dated February 9, 1967
28. Seiden LS, Carlsson A (1964) Brain and heart catecholamine levels after L-dopa administration in reserpine treated mice: correlation with a conditioned avoidance response. Psychopharmacologia (Berl) 5:178-181
29. Hanson LCF (1965) The disruption of conditioned avoidance response following selective depletion of brain catecholamines. Psychopharmacologia (Berl) 8:100-110
30. Carlsson A (1965) Drugs which block the storage of 5-hydroxytryptamine and related amines. In: Eichler O, Farah A (eds) 5-Hydroxytryptamine and related indole alkylamines. Handbook of Experimental Pharmacology, vol 19 Springer, Heidelberg, p 529-592
31. Bertler Å, Rosengren E (1966) Possible role of brain dopamine. Pharmacol Rev 18:769-773
32. Vogt M (1973) Functional aspects of the role of catecholamines in the central nervous system. Br Med Bull 29:168-172
33. Jasper HH (1970) Neurophysiological mechanisms in parkinsonism. In: Barbeau A, McDowell FH (eds) L-dopa and Parkinsonism. FA Davies, Philadelphia, pp 406-411
34. Ward AA (1970) Physiological implications in the dyskinesias. In: Barbeau A, McDowell FH (eds) L-dopa and Parkinsonism. FA Davies, Philadelphia, pp 151-159
35. Moore RY (1970) The nigrostriatal pathway demonstrated by anterograde degeneration. In: Barbeau A, McDowell FH (eds) L-dopa and Parkinsonism. FA Davies, Philadelphia, pp 143-149
36. Lloyd K, Davidson L, Hornykiewicz O (1973) Metabolism of levodopa in the human brain. Adv Neurol 3:173-188
37. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petric A (1974) Bromocriprine in parkinsonism. Br Med J 4:442-444